In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy.

Nony, P; Guastalla, J P; Rebattu, P; Landais, P; Lievre, M; Bontemps, L; Itti, R; Beaune, J; Andre-Fouet, X; Janier, M

Nony, P; Guastalla, J P; Rebattu, P; Landais, P; Lievre, M; Bontemps, L; Itti, R; Beaune, J; Andre-Fouet, X; Janier, M.

Affiliation

Nony P; Department of Clinical Pharmacology, Cardiovascular Hospital, Lyon, France. pn@upcl.univ-lyon1.fr

Cancer Chemother Pharmacol ; 45(5): 375-80, 2000.

Article in En | MEDLINE | ID: mdl-10803920

Subject(s)

Antibiotics, Antineoplastic/adverse effects; Coronary Circulation/drug effects; Doxorubicin/adverse effects; Heart/drug effects; Myocardium/metabolism; Neoplasms/drug therapy; Aged; Citric Acid Cycle/drug effects; Electrocardiography/drug effects; Female; Humans; Longitudinal Studies; Middle Aged; Neoplasms/metabolism; Oxidation-Reduction; Tomography, Emission-Computed

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Coronary Circulation / Heart / Antibiotics, Antineoplastic / Myocardium / Neoplasms Type of study: Observational_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2000 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links